SHIM
TXG icon

Stone House Investment Management’s 10x Genomics TXG Stock Holding History

Stone House Investment Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$403 Hold
19
– – ﹤0.01% 844
2025
Q4 		$310 Buy
+19
New +$287 ﹤0.01% 754

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stone House Investment Management's TXG Position: Q1 2026 in Review

Stone House Investment Management held its 10x Genomics (TXG) position steady in Q1 2026 at 19 shares worth $403. The position accounts for ﹤0.01% of the portfolio, ranked #844.

Stone House Investment Management first reported a position in TXG in Q4 2025 and has held it in 2 quarters since. 329 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

  • Stone House Investment Management held 19 shares of 10x Genomics worth $403 as of Q1 2026.
  • Stone House Investment Management left its 10x Genomics share count unchanged in Q1 2026.
  • 10x Genomics made up ﹤0.01% of Stone House Investment Management's portfolio in Q1 2026, its #844 holding.
  • Stone House Investment Management first reported a position in 10x Genomics in Q4 2025 and has held it in 2 quarters since.
  • 329 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on Stone House Investment Management's 13F filing for Q1 2026, filed 22 Apr 2026.